Literature DB >> 9519873

Expression of RET 3' splicing variants during human kidney development.

S M Ivanchuk1, S M Myers, L M Mulligan.   

Abstract

The mature mammalian kidney arises through a series of reciprocal inductive interactions between two different cell groups, the ureteric bud epithelium and the metanephric mesenchyme. The RET receptor tyrosine kinase is required for induction and development of the metanephric kidney. Differential splicing at the 3' end of RET results in transcripts encoding three isoforms that differ with respect to their C-terminal 9 (RET9), 51 (RET51) or 43 (RET43) amino acids. In vitro assays have identified differences in the abilities of the RET9 and RET51 isoforms to induce differentiation suggesting functional differences between these proteins. We examined the relative expression levels of the three RET 3' splicing variants in developing human kidney using semi-quantitative RT-PCR. We observed consistent expression of the RET9 and RET43 variants in kidney samples spanning 7.5 through 24 weeks gestation. At early gestational ages (7.5-8.5 weeks), RET51 expression was very low (+/-5%) compared to RET9; however, a rapid seven fold increase in expression was detected by 9 weeks. Our data suggest that RET51 may contribute to differentiation-related events occurring after 8.5 weeks gestation rather than to induction of the human kidney.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519873     DOI: 10.1038/sj.onc.1201622

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

Review 1.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

2.  Alternative splicing results in RET isoforms with distinct trafficking properties.

Authors:  Douglas S Richardson; David M Rodrigues; Brandy D Hyndman; Mathieu J F Crupi; Adrian C Nicolescu; Lois M Mulligan
Journal:  Mol Biol Cell       Date:  2012-08-08       Impact factor: 4.138

3.  Pediatric Medullary Thyroid Carcinoma.

Authors:  Dmytro Starenki; Jong-In Park
Journal:  J Pediatr Oncol       Date:  2015

4.  Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma.

Authors:  Chiara Mulè; Raffaele Ciampi; Teresa Ramone; Alessandro Prete; Antonio Matrone; Virginia Cappagli; Liborio Torregrossa; Fulvio Basolo; Rossella Elisei; Cristina Romei
Journal:  Biomolecules       Date:  2021-10-19

5.  A rare haplotype of the RET proto-oncogene is a risk-modifying allele in hirschsprung disease.

Authors:  Paola Griseri; Barbara Pesce; Giovanna Patrone; Jan Osinga; Francesca Puppo; Monica Sancandi; Robert Hofstra; Giovanni Romeo; Roberto Ravazzolo; Marcella Devoto; Isabella Ceccherini
Journal:  Am J Hum Genet       Date:  2002-09-04       Impact factor: 11.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.